{
  "docId": "019de074-2973-7208-9395-338d3116556a",
  "docSlug": "4059563425860536cb0bf09c6eb6bba5",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 29 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 29,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "Includes specific caveats regarding study power and dosing duration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2973-7208-9395-338d3116556a/20",
  "deckHref": "/decks/019de074-2973-7208-9395-338d3116556a",
  "deckJsonHref": "/decks/019de074-2973-7208-9395-338d3116556a.json",
  "deckAnchorHref": "/decks/019de074-2973-7208-9395-338d3116556a#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Mean Change from Baseline %BSA affected in treated areas",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f17692be-9146-475d-bff0-d13360ab195f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.12,
        "y": 0.6
      },
      "kind": "legend",
      "text": "Cohort 3 Patients dosed 1% ointment, 30% BSA, once per day",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13151687-474b-4df3-bec4-c505bf6fde6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.65,
        "y": 0.4
      },
      "kind": "legend",
      "text": "0.25% QD 10%BSA 7d, 1% QD 10%BSA 7d, 1% QD 30%BSA 14d, 1% BID 30%BSA 14d, PBO 7d, PBO 14d",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13560cbd-391d-4c5f-9c4e-8c23e25be6d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.22,
        "y": 0.65
      },
      "kind": "legend",
      "text": "Cohort 4 Patients dosed 1% ointment, 30% BSA, twice per day",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13f733b6-9565-47a1-a621-915f02039e5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Caveats: Phase Ib was NOT powered to meaningfully assess efficacy - only 6 patients dosed with active per group. Maximum duration of dosing 14 days (EASI score changes typically measured at 28 days)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46386677-dcc9-4894-954f-a25fba4778ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "EASI: Eczema Area and Severity Index",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1af6da7-8744-49ea-a739-2b1b5064f247",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "BEN-2293 - indicative data from Phase Ib",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88a577cc-d566-4f35-b0cd-55ea59c42304",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 16,
      "beatId": "3b0e5288-2029-43c9-ada8-d64afac944d7",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The call to action is clear, with a roadmap and ask for investors",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 19,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b2de1916-1b79-40d9-9966-3475d4152b9a",
      "evidence": "The presentation highlights the limitations of current treatments",
      "position": 0,
      "objective": "Highlight the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}